(Q34998102)

5 August 2017

1 reference

title

Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection (English)

1 reference

5 August 2017

1 reference

Robert Orenstein

1

1 reference

PubMed ID

12432973

5 August 2017

Nickolaos Tsogas

series ordinal

2

1 reference

PubMed ID

12432973

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

22

1 reference

5 August 2017

11

1 reference

5 August 2017

1468-1478

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

5 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Antiretroviral drug toxicity -- a challenge for the hepatologist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Evaluation of hepatic injury arising during fluconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Jaundice in HIV positive haemophiliac

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Fluconazole-induced jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatic reactions associated with ketoconazole in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Ketoconazole-induced fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Fatal hepatitis associated with ketoconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatic injury associated with itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Overview of the tolerability profile of clarithromycin in preclinical and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Clinical toleration and safety of azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatic side-effects of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Prolonged cholestasis due to trimethoprim sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Inadvertent rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Adverse Reactions to Trimethoprim-Sulfamethoxazole in Patients with the Acquired Immunodeficiency Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Acyclovir tolerance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Defining patient risks from expanded preventive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

The use of anabolic agents in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Hepatotoxic effects of the anabolic/androgenic steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Adverse effects of anabolic steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1468.33702

10.1592/PHCO.22.16.1468.33702

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12432973